Sinopharm and Sinovac COVID-19 vaccines; Prevalence and risk factors for post full vaccination weak immunity.

Objective: To see the prevalence and risk factors for post full vaccination (Sinopharm Sinovac COVID-19 vaccines) weak immunity in persons with no history of viral exposure. Study Design: Prospective Observational. Setting: Syed Research Centre, Sialkot. Period: Nov 2021 to Feb 2022. Material & Methods: Eighty two individuals (male/female, aged: 24-70 years) were enrolled from District Sialkot (Pakistan). Two doses Sinopharm or vaccine administered each participant before blood sampling. The quantity spike immunoglobulin G against SARS-CoV-2 (5-Antigen) was detected serum using chemiluminescence immunoassay technique [threshold titer: 7.1 (detection), 105. 63 (seroprotection), 492.96 BAU/mL (strong humoral response)]. Results: Overall, 96.3% seropositivity, 89% seroprotection, 37.8% (n = 31) immune response recorded. Whereas, mean antibody titer found be 2312.02 (range: 0.0 – 28711.74) BAU/mL. A vaccinated male had approximately 4 folds (95%CI: 1.297 11.504; p .002) more likelihood than females. Similarly, rate poor immunological outcome higher >24.9 Kg/m2 (69.2%, n 27) body mass index compared ≤24.9 Kg/m2. person vulnerable participants (RR 2.351; 95%CI 1.327 4.167; .002; 57.6% vs. 24.5%, respectively). Co-occurrence age (>47 BMI (>24.9 Kg/m2) existed 11 28 males (39.3%) impaired immunogenicity. Conclusion: high is alarming. Gender, BMI, type amongst predictors diminished response.